Halozyme Therapeutic (HALO) |
|
23.26 -0.34 (-1.44%)
|
06-04 16:00 |
|
Open: |
23.35 |
Pre. Close: |
23.6 |
|
High:
|
23.8 |
Low:
|
23.105 |
|
Volume:
|
1,445,007 |
Market Cap:
|
3,159M |
|
|
|
|
Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
23.829 - 23.977 |
23.977 - 24.083 |
|
Low:
|
22.748 - 22.933 |
22.933 - 23.064 |
|
Close:
|
23.017 - 23.288 |
23.288 - 23.479 |
|
Technical analysis |
as of: 2020-06-04 4:32:05 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 28.32 One year: 29.99 |
| Support: |
Support1: 21.92 Support2: 18.24 |
| Resistance: |
Resistance1: 24.24 Resistance2: 25.68 |
| Pivot: |
24.00  |
| Moving Average: |
MA(5): 23.92 MA(20): 23.98
MA(100): 20.32  MA(250): 18.26 |
| MACD: |
MACD(12,26): 0.53 Signal(9): 0.79 |
| Stochastic oscillator: |
%K(14,3): 39.10 %D(3): 47.47 |
| RSI: |
RSI(14): 49.92 |
| 52-week: |
High: 25.68 Low: 12.71 Change(%): 50.0 |
| Average Vol(K): |
3-Month: 165317 10-Days: 139391 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.HALO has closed above bottom band by 2.0%. Bollinger Bands are 60.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to HALO's normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 04 Jun 2020
Halozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX® Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma - PRNewswire
Tue, 12 May 2020
Halozyme Therapeutics Inc (HALO) Q1 2020 Earnings Call Transcript - The Motley Fool
Thu, 14 May 2020
Halozyme To Receive $15 Million Milestone Payment From Janssen - PRNewswire
Fri, 05 Jun 2020
EC approval for subcutaneous Darzalex - The Pharma Letter
Wed, 13 May 2020
Barclays Sticks to Their Hold Rating for Halozyme Therapeutics - Yahoo Finance
Thu, 28 May 2020
Halozyme To Present At Upcoming Virtual Investor Conferences - Yahoo Finance
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
136 |
| Shares Float (M) |
127 |
|
% Held by Insiders
|
1.20 |
|
% Held by Institutions
|
101.78 |
|
Shares Short (K)
|
15,480 |
|
Shares Short P. Month (K)
|
13,990 |
Stock Financials |
|
EPS
|
-0.560 |
|
EPS Est This Year
|
-0.130 |
|
EPS Est Next Year
|
-0.790 |
|
Book Value (p.s.)
|
0.430 |
|
Profit Margin
|
-48.75 |
|
Operating Margin
|
-27.61 |
|
Return on Assets (ttm)
|
-6.2 |
|
Return on Equity (ttm)
|
-50.4 |
|
Qtrly Rev. Growth
|
-55.5 |
|
Gross Profit (p.s.)
|
0.198 |
|
Sales Per Share
|
1.210 |
|
EBITDA (p.s.)
|
-0.319 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-86 |
|
Levered Free Cash Flow (M)
|
-33 |
Stock Valuations |
|
PE Ratio
|
-41.54 |
|
PEG Ratio
|
|
|
Price to Book value
|
54.09 |
|
Price to Sales
|
19.22 |
|
Price to Cash Flow
|
-36.80 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
